Labcorp Q3 2026: 6.9% revenue growth, EPS $3.22, full-year guidance raised

What happened

Labcorp reported Q3 2026 revenue of $3.81 billion, up 6.9% year-over-year, with diluted EPS of $3.22, and raised its full-year 2026 guidance. The revenue growth was driven by continued strength in Diagnostics and Biopharma Laboratory Services, consistent with the company's mid-single-digit organic growth plus acquisition contributions highlighted in the master report. While the EPS increase from $3.14 a year ago is modest at roughly 2.5%, the company's ability to beat expectations and raise guidance suggests operational execution is on track. However, the quarter does not materially alter the key overhangs: potential PAMA/CLFS reimbursement cuts from 2026 and LDT regulatory uncertainty, which the master report identified as significant risks. At the current price near $268, still trading well above the $166 DCF-based intrinsic value, the valuation remains rich, and the positive results reinforce the view that the market has already priced in strong execution, offering limited margin of safety.

Implication

Labcorp's Q3 2026 results show that its core business remains resilient, with revenue growth of 6.9% and full-year guidance raised, which is a positive signal for the company's ability to withstand competitive and reimbursement pressures. However, the modest EPS growth and the continued premium valuation suggest that the market has already anticipated these results, and the stock's upside from current levels may be limited. The pending PAMA/CLFS rate cuts and potential FDA regulation of lab-developed tests remain significant wildcards that could pressure margins and cash flows in 2026 and beyond. While the raised guidance implies management confidence, the balance sheet leverage and M&A integration risks noted in the master report still warrant caution. Investors should monitor reimbursement policy developments and M&A execution, and consider adding to positions only on meaningful valuation pullbacks toward the low $200s or if the shares approach a more reasonable FCF yield.

Thesis delta

The positive Q3 2026 results and raised guidance modestly improve the near-term outlook, but the fundamental valuation and regulatory risks remain largely unchanged. The master report's WAIT stance is reaffirmed; no shift to BUY is warranted given the stock still trades significantly above intrinsic value. A more constructive view would require sustained FCF growth and resolution of reimbursement uncertainties.